The ischemic stroke pipeline market is expected to grow at the highest pace owing to rising demand for therapeutics to treat ischemic stroke.
Ischemic stroke, also known as cerebral infarction, accounts for approximately 87 percent of all stroke cases and is caused by obstruction of blood flow to the brain due to a blood clot or thrombus. Currently, there are limited treatment options for ischemic stroke patients with thrombolysis such as tissue plasminogen activator (tPA) approved only for treatment within 4.5 hours of onset of symptoms. The pipeline for ischemic stroke therapeutics focuses on developing drugs that can extend the treatment window or provide neuroprotection.
The global ischemic stroke pipeline market is estimated to be valued at US$ 1.41 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the ischemic stroke pipeline market are GNT Pharma,ZZ Biotech LLC,JIXING Pharmaceuticals,AbbVie,Meridigen Biotech Co., Ltd. Several companies are focused on developing innovative drug candidates targeting different mechanisms of action with extended treatment windows.
The growing incidence of ischemic stroke coupled with lack of effective treatment therapies available is expected to drive the demand for novel therapeutics in the pipeline. According to WHO, annually 15 million people suffer a stroke worldwide, out of which 5 million die and another 5 million are permanently disabled.
Technological advancements in areas such neuroimaging and biomarkers are facilitating efficient clinical development of drugs in the pipeline. Companies are leveraging advanced techniques for early identification of potentially effective candidates and clinical selection of patients.
Market Trends
Personalized medicine approach leveraging biomarkers - Biomarkers are playing an important role in identifying the right patients for clinical trials and monitoring drug response. Companies are exploring using specific biomarkers to develop personalized treatment regimens.
focus on combination therapies - Due to multifactorial nature of ischemic stroke, companies are investigating combination therapies targeting different mechanisms simultaneously for synergistic treatment effects.
Market Opportunities
Neuroprotective therapies for extended treatment window - Currently, the only FDA approved therapy tPA has a narrow treatment window of 4.5 hours. Therapies aiming to provide neuroprotection beyond this window present lucrative opportunities.
Stem cell therapy - Stem cell based strategies hold promise due to their neuro regenerative and protective properties. Favorable regulatory guidelines and ongoing clinical trials will drive their commercialization in the future.
Impact of COVID-19 on the Ischemic Stroke Pipeline Market
The COVID-19 pandemic has significantly impacted the growth of the ischemic stroke pipeline market globally. Due to lockdowns and movement restrictions imposed across various countries to curb the spread of the virus, patient diagnosis and hospital visits witnessed a steep decline during 2020-2021. International travel restrictions also disrupted clinical trials and delayed new product launches in the market. Supply chain disruptions further constrained the availability of key drugs and medical devices.
However, the post-COVID period is expected to see renewed growth in the market. With restrictions being lifted and healthcare systems adapting to the new normal, the number of patient diagnoses and hospital visits are recovering. Pharmaceutical companies are also speeding up their clinical research and product development activities. Several new drugs targeting unmet needs in ischemic stroke prevention and treatment are likely to enter the market. Telehealth and digital health solutions adopted during the pandemic are also helping expand access to stroke care. The long-term growth outlook for the market remains positive with increasing prevalence of risk factors like hypertension, obesity, diabetes etc.
Get more insights on this topic : https://www.zupyak.com/p/4415202/t/ischemic-stroke-pipeline-market-offers-growth-opportunities-due-to-increasing-prevalence-of-strokes
Geographical Regions with Highest Market Concentration
North America currently holds the largest share of the global ischemic stroke pipeline market in terms of value, estimated at over 35% in 2024. This is attributed to presence of advanced healthcare infrastructure, higher diagnosis rates, and growing R&D investments by key players in the US and Canada.
Europe is another major regional market supported by rising government focus on improving stroke care pathways and outcomes. Countries like Germany, UK, France, Italy hold over 45% share of the European market.
Fastest Growing Regional Market
The Asia Pacific region is poised to witness the fastest growth in the global ischemic stroke pipeline market during the forecast period of 2024-2031. This can be accredited to growing elder population base susceptible to stroke, improving access to healthcare in developing countries, and increasing focus of international players to tap into opportunities in emerging Asia Pacific markets. China and India individually represent around 25% of the global economic burden of stroke and thus present lucrative growth prospects.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
